PGEN Files Form 144 for 5,000,000 Shares on Nasdaq

Rhea-AI Filing Summary

Precigen, Inc. (PGEN) filed a Form 144 notice reporting a proposed sale of 5,000,000 common shares with an aggregate market value of $19,625,000. The filing lists the broker as Charles Schwab Corp and names Nasdaq as the exchange, with an approximate sale date of 09/18/2025. The filing discloses the acquisition history for the shares being sold, showing multiple purchases and initial/public offerings between 2013 and 2018 that total the lots listed. The filer reports 297,972,920 shares outstanding, and notes there were no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: A planned sale of 5.0M PGEN shares (~$19.6M) is disclosed; size is modest relative to total shares outstanding.

The Form 144 indicates an institutional brokered sale of 5,000,000 common shares on Nasdaq, with an aggregate market value of $19.625 million and about 298 million shares outstanding. The filing details that the shares were acquired across several public offerings and open-market purchases from 2013 to 2018. There are no reported sales by the filer in the prior three months. From an analyst perspective, the transaction is transparent and documented, but the size represents only a small percentage of the company’s outstanding shares, suggesting limited immediate dilution or market-moving risk based solely on this notice.

Corporate Governance Expert

TL;DR: The filing meets Rule 144 disclosure expectations and includes the required seller representation regarding material information.

The Form 144 provides the broker name, intended sale date, class and number of shares, acquisition dates and payment methods, and affirms the seller’s representation about knowledge of material nonpublic information. The absence of recent sales in the past three months and the detailed acquisition history align with compliance norms for insiders or affiliates disposing of securities under Rule 144. The document contains the standard legal cautions and signature attestation language, indicating procedural completeness for regulatory purposes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp 3000 Schwab Way Westlake TX 76262	5000000	19625000.00	297972920	09/18/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/27/2015	Public Offering	Issuer			478100	01/27/2015	Cash
Common	07/03/2018	Public Offering	Issuer			3112507	07/03/2018	Cash
Common	08/13/2013	Initial Public Offering	Issuer			896437	08/13/2013	Cash
Common	12/07/2015	Open Market Purchase	Issuer			227120	12/07/2015	Cash
Common	12/11/2015	Open Market Purchase	Issuer			119023	12/11/2015	Cash
Common	05/18/2016	Open Market Purchase	Issuer			39998	05/18/2016	Cash
Common	08/11/2017	Open Market Purcahse	Issuer			126815	08/11/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Precigen (PGEN) disclose?

The filing discloses a proposed sale of 5,000,000 common shares with an aggregate market value of $19,625,000, to be executed via Charles Schwab on Nasdaq around 09/18/2025.

How many shares of PGEN are outstanding according to the filing?

The filing reports 297,972,920 shares outstanding.

Were any PGEN securities sold by the filer in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

What is the acquisition history for the shares being sold?

The shares were acquired in multiple transactions between 2013 and 2018, including an initial public offering, public offerings, and several open-market purchases; payment was in cash.

Does the filer assert knowledge of undisclosed material information?

Yes. By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.